



24 August 2021

**Nuformix plc**  
**(“Nuformix” or the “Company”)**

**Results of Annual General Meeting**

**Nuformix plc** (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that all resolutions proposed at its Annual General Meeting held today were duly passed. The results are set out below:

The Q&A for AGM will be available on the website later this week.

	<b>Resolution</b>	<b>Ordinary/ Special</b>	<b>For</b>		<b>Against</b>		<b>Total votes cast</b>
			No. of votes	%	No. of votes	%	
1	To receive the annual report and accounts for the year ended 31 March 2021	Ordinary	41,314,178	99.97%	10,888	0.03%	41,325,066
2	To approve the Remuneration Policy	Ordinary	40,759,964	98.58%	586,866	1.42%	41,346,830
3	To re-appoint Annual Report on Remuneration	Ordinary	40,862,374	98.88%	462,692	1.12%	41,325,066
4	To re-appoint Alastair Riddell as a director	Ordinary	40,811,768	98.71%	531,941	1.29%	41,343,709
5	To re-appoint Julian Gilbert as a director	Ordinary	41,211,768	99.68%	131,941	0.32%	41,343,709
6	To re-appoint s Madeleine Kennedy as a director	Ordinary	41,162,427	99.56%	181,282	0.44%	41,343,709
7	To re-appoint Anne Brindley as a director	Ordinary	40,811,768	98.71%	531,941	1.29%	41,343,709

8	To re-appoint haysmacintyre as auditor	Ordinary	41,211,768	99.97%	10,888	0.03%	41,222,656
9	To authorise the Directors to determine the auditor's fees.	Ordinary	40,953,492	99.05%	393,338	0.95%	41,346,830
10	To authorise the Directors to allot shares.	Ordinary	40,362,427	97.50%	1,036,813	2.50%	41,399,240
11	To authorise the Directors to disapply pre-emption rights.	Special	39,584,831	95.50%	1,864,409	4.50%	41,449,240
12	To authorise the Company to purchase its own shares.	Special	41,286,601	99.61%	162,639	0.39%	41,449,240
13	To authorise calling of a general meeting on 14 clear days' notice.	Special	41,438,352	99.97%	10,888	0.03%	41,449,240

<sup>1</sup> A vote withheld is not a vote under English law and is therefore not included in the calculation of votes for and against a resolution.

In accordance with Listing Rule 9.6.2, a copy of all resolutions passed as special business will shortly be available for inspection at the National Storage Mechanism document viewing facility at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

#### Enquiries:

##### Nuformix plc

Dr Alastair Riddell, Non-Executive Chairman  
Dr Anne Brindley, CEO

via Walbrook

##### Allenby Capital Limited

Nick Athanas / George Payne (Corporate Finance)  
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking)

+44 (0) 20 3328 5656

##### Walbrook PR

Anna Dunphy / Phillip Marriage / Kiki Zaccagnini

[nuformix@walbrookpr.com](mailto:nuformix@walbrookpr.com) or +44 (0)20 7933 8780

Tel: +44 (0)7876 741 001 / +44 (0)7980 541 893

**About Nuformix**

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit [www.nuformix.com](http://www.nuformix.com).